Now that we have had our first scientific successes in precision medicine and even a new federal precision medicine initiative, will it help us treat disease? Even if we can more precisely diagnose patients and prognosticate about their future, does this mean we will have the right treatments for them? Do we have to wait for the traditional flow of science through the large pharmaceutical companies to get new effective drugs? Will engineering, whether in gene editing or device hacking, revolutionize care?
Precision Medicine: Rogue Therapeutics will directly address these questions and give a premeditatedly iconoclastic perspective. Our keynote speaker, Karen Aiach, did not start in medicine or pharmaceuticals, but specifically because of her long clinical journey with her daughter has founded a rapidly-growing biotech company for the treatment of the disorders of her child and those of others. We will also have panels featuring similarly patient-focused and even impatient approaches to finding therapies. As you can see from the agenda, this symposium follows very much in the spirit of our successful conference last year, Precision Medicine: Patient Driven.
The Inn at Longwood Medical
342 Longwood Avenue, Boston, MA 02115
617-731-4700 Click HERE to reserve at the group rate.
Cut-off date for group rate: May 31, 2016
Courtyard Marriott Brookline
40 Webster Street (Coolidge Corner), Brookline, MA 02446
617-734-1393 Click HERE to reserve at the group rate.
Cut-off date for group rate: June 20, 2016
Agenda
8:00 – 8:30 am Continental Breakfast and Check-in
8:30 – 9:00 am Welcome and Opening Remarks – Zak Kohane
9:00 – 10:00 am Keynote – Karen Aiach, Lysogene: Rare Informs the Common
10:00 – 10:15 am Break
10:15 – 11:45 am PANEL 1: What is driving Precision Medicine?
Ashish Jha, Harvard School of Public Health (moderator)
Carey Goldberg, WBUR
Gail Marcus, ELI Healthcare Consultant
Joseph Newhouse, Health Care Policy, Harvard Medical School
11:45 am – 12:45 pm Lunch
12:45 – 2:15 pm PANEL 2: What happens when patients take over?
Bill Gahl, Undiagnosed Diseases Network (moderator)
Matt Might, University of Utah
Eric Minikel & Sonia Vallabh, Broad Institute
Alison Skrinar, UltraGenyx Pharmaceutical
2:15 – 2:30 pm Break
2:30 – 3:45 pm PANEL 3: Marijuana: recreational to medicinal?
Donald Abrams, University of California San Francisco
Kari Franson, University of Colorado School of Pharmacy
Ryan Vandrey, Johns Hopkins University
Larry Wolk, Colorado State Public Health
3:45 – 5:00 pm PANEL 4: Will engineering disrupt therapeutics?
